am 251 has been researched along with Neuralgia in 11 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 5.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| "AM404 attenuated mechanical and cold hyperalgesia with minimal effects on motor coordination." | 1.62 | Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model. ( Hara, K; Haranishi, Y; Terada, T, 2021) |
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 1.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| "Paclitaxel produced mechanical and cold allodynia without altering nestlet shredding or marble burying behaviors." | 1.48 | Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. ( Hohmann, AG; Iyer, V; Makriyannis, A; Saberi, SA; Slivicki, RA; Vemuri, VK, 2018) |
| "MCS reversed mechanical hyperalgesia, inhibited astrocyte and microglial activity, decreased proinflammatory cytokine staining, enhanced CB2 staining, and downregulated P2X4 receptors in the DHSC ipsilateral to sciatic injury." | 1.42 | The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain? ( Fonoff, ET; Lopes, PS; Pagano, RL; Silva, GD, 2015) |
| "Mechanical allodynia and thermal hyperalgesia were evaluated in 436 male C57BL/6, cnr1KO and cnr2KO mice in the presence or absence of cannabinoid CB₁ (AM251) or CB₂ (AM630) receptor antagonists in a mouse model of neuropathic pain." | 1.40 | Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. ( Beaulieu, P; Bouchard, JF; Charron, S; Desroches, J, 2014) |
| "Models of neuropathic pain are associated with elevated spinal levels of endocannabinoids (ECs) and altered expression of cannabinoid receptors on primary sensory afferents and post-synaptic cells in the spinal cord." | 1.36 | Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. ( Barrett, DA; Chapman, V; de Lago, E; Fernández-Ruiz, J; Gray, RA; Jhaveri, MD; Kendall, DA; Richardson, D; Sagar, DR, 2010) |
| "Thermal hyperalgesia was significantly ameliorated in a dose-dependent manner with systemically administered WIN." | 1.36 | Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain. ( Ahmed, MM; Allcock, B; Gerovac, TA; McChesney, S; Miranpuri, GS; Patel, AU; Rajpal, S; Resnick, DK; Sweeney, C; Tilghman, JI, 2010) |
| "Paracetamol dose-dependently decreased mechanical allodynia and lowered nociceptive scores associated with hyperalgesia testing." | 1.34 | The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. ( Beaulieu, P; Dani, M; Guindon, J; Lambert, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Haranishi, Y | 1 |
| Hara, K | 1 |
| Terada, T | 1 |
| Malvestio, RB | 1 |
| Medeiros, P | 1 |
| Negrini-Ferrari, SE | 1 |
| Oliveira-Silva, M | 1 |
| Medeiros, AC | 1 |
| Padovan, CM | 1 |
| Luongo, L | 1 |
| Maione, S | 2 |
| Coimbra, NC | 1 |
| de Freitas, RL | 1 |
| Segat, GC | 1 |
| Manjavachi, MN | 1 |
| Matias, DO | 1 |
| Passos, GF | 1 |
| Freitas, CS | 1 |
| Costa, R | 1 |
| Calixto, JB | 1 |
| De Gregorio, D | 1 |
| McLaughlin, RJ | 1 |
| Posa, L | 1 |
| Ochoa-Sanchez, R | 1 |
| Enns, J | 1 |
| Lopez-Canul, M | 1 |
| Aboud, M | 1 |
| Comai, S | 1 |
| Gobbi, G | 1 |
| Slivicki, RA | 1 |
| Saberi, SA | 1 |
| Iyer, V | 1 |
| Vemuri, VK | 1 |
| Makriyannis, A | 1 |
| Hohmann, AG | 1 |
| Desroches, J | 1 |
| Charron, S | 1 |
| Bouchard, JF | 1 |
| Beaulieu, P | 2 |
| Petrenko, AB | 1 |
| Yamazaki, M | 1 |
| Sakimura, K | 1 |
| Kano, M | 1 |
| Baba, H | 1 |
| Silva, GD | 1 |
| Lopes, PS | 1 |
| Fonoff, ET | 1 |
| Pagano, RL | 1 |
| Sagar, DR | 1 |
| Jhaveri, MD | 1 |
| Richardson, D | 1 |
| Gray, RA | 1 |
| de Lago, E | 1 |
| Fernández-Ruiz, J | 1 |
| Barrett, DA | 1 |
| Kendall, DA | 1 |
| Chapman, V | 1 |
| Ahmed, MM | 1 |
| Rajpal, S | 1 |
| Sweeney, C | 1 |
| Gerovac, TA | 1 |
| Allcock, B | 1 |
| McChesney, S | 1 |
| Patel, AU | 1 |
| Tilghman, JI | 1 |
| Miranpuri, GS | 1 |
| Resnick, DK | 1 |
| Dani, M | 1 |
| Guindon, J | 1 |
| Lambert, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet[NCT04088929] | Phase 2 | 32 participants (Actual) | Interventional | 2019-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT04679545] | Phase 2 | 50 participants (Anticipated) | Interventional | 2020-12-10 | Recruiting | ||
| Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury[NCT04057456] | Phase 3 | 140 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT05766969] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for am 251 and Neuralgia
| Article | Year |
|---|---|
Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model.
Topics: Animals; Arachidonic Acids; Capsaicin; Constriction; Disease Models, Animal; Endocannabinoids; Hyper | 2021 |
Cannabidiol in the prelimbic cortex modulates the comorbid condition between the chronic neuropathic pain and depression-like behaviour in rats: The role of medial prefrontal cortex 5-HT
Topics: Animals; Cannabidiol; Chronic Disease; Cobalt; Depression; Limbic System; Microinjections; Neuralgia | 2021 |
Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phyto | 2017 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Topics: Amidohydrolases; Analgesics, Opioid; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; | 2018 |
Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Topics: Animals; Arachidonic Acids; Behavior, Animal; Endocannabinoids; Glycerides; Hyperalgesia; Male; Mice | 2014 |
Augmented tonic pain-related behavior in knockout mice lacking monoacylglycerol lipase, a major degrading enzyme for the endocannabinoid 2-arachidonoylglycerol.
Topics: Animals; Arachidonic Acids; Benzodioxoles; Cannabinoid Receptor Modulators; Endocannabinoids; Glycer | 2014 |
The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Calcium-Binding Proteins; Cytokines; Deep B | 2015 |
Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Topics: Anesthesia; Animals; Arachidonic Acids; Camphanes; Cannabinoid Receptor Modulators; Central Nervous | 2010 |
Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Topics: Analgesics; Analysis of Variance; Animals; Benzoxazines; Dose-Response Relationship, Drug; Hot Tempe | 2010 |
The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arachidonic Acids; Cannabinoid Receptor Antagonist | 2007 |